Therapeutic potentials of itasetron (DAU 6215), a novel 5-HT3 receptor antagonist, in the treatment of central nervous system disorders

CNS Drug Reviews

Volumn 2, Issue 2, 1996, Pages 195-213

  Passani, M Beatrice ^a   Corradetti, Renato ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

5HT3 receptor antagonists; Antianxiety; Antiemetic; Antipsychotic; Cognition enhancer; DAU 6215; Dolasetron; Granisetron; Itasetron; Ondansetron; Tropisetron; Zacopride; Zatosetron

Indexed keywords

ITASETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR;

ANXIETY NEUROSIS; COGNITIVE DEFECT; DRUG RECEPTOR BINDING; DRUG USE; HUMAN; NONHUMAN; PSYCHOSIS; RECEPTOR DENSITY; REVIEW;

EID: 0030038264     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1996.tb00297.x     Document Type: Review

References (94)

1. 3H]LY278584 binding sites in human brain. J Neurochem 1993;60:730-737.
2. 3 antagonists. Psychopharmacology 1990;100:459-463.
3. 3 receptor-mediated antinociception: Possible release of GABA. J Neurosci 1991;11:1881-1888.
4. 3 receptor antagonist, fails to alter the number of spontaneously active midbrain dopamine neurons. Eur J Pharmacol 1990;175:347-350.
5. 3 recognition sites in human brain tissue. J Neurochem 1989;53:1787-1793.
6. 3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature 1989;338:762-763.
7. 3 receptor antagonist on cognition in rodents and primates. Pharmacol Biochem Behav 1990;35:955-962.
8. 3 receptor recognition sites in Alzheimer's disease. NeuroReport 1990;1:253.
9. 3 receptor. Abstr Soc Neurosci 1994;20:1156.
10. Beck SG, Clarke WP, Goldfarb J. Spiperone differentiates multiple 5-hydroxytryptamine responses in rat hippocampal slices in vitro. Eur J Pharmacol 1985;116:195-197.
11. Benloucif S, Keegan MJ, Galloway MP. Serotonin-facilitated dopamine release in vivo: Pharmacological characterization. J Pharmacol Exp Ther 1993;265:373-377.
12. 3 receptor antagonist with anxiolytic-like properties. Psychopharmacology 1993;110:257-264.
13. 3 receptors in the striatum. J Pharmacol Exp Ther 1989;251:803-809.
14. Blandina P, Goldfarb J, Walcott J, Green JP. Serotonergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices. J Pharmacol Exp Ther 1991;256:341-347.
15. 3 antagonist, in animal models of anxiety. Pharmacol Res 1993;27:151-163.
16. 3 receptor antagonist, selectively antagonizes scopolamine-induced deficit in a passive avoidance task, but not scopolamine-induced hypermotility in rats. J Pharm Pharmacol 1993;45:841-843.
17. 3 receptor antagonists as anti-emetics. TiPS 1991;12:46-48.
18. Bunney BS. Antipsychotic drug effects on the electrical activity of dopaminergic neurons. TINS 1984;7: 212-215.
19. Bunney BS, Aghajanian GK. Antipsychotic drugs and central dopaminergic neurons: A model for predicting therapeutic efficacy and incidence of extrapyramidal side effects. In: Sudilovsky S et al., eds. Predictability in Psychopharmacology: Preclinical and Clinical Observations. New York: Raven Press, 1975.
20. 3 antagonist on drug-induced stimulation of dopamine release. Eur J Pharmacol 1989;164:515-519.
21. Carey GJ, Costall B, Domeney AM, et al. Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset. Pharmacol Biochem Behav 1992;42:75-83.
22. 3 receptor by 1-phenylbiguanide increase dopamine release in the rat nucleus accumbens. Brain Res 1991;543:354-357.
23. 3 receptor antagonist ICS 205-930. Pharmacol Toxicol 1991;69:105-111.
24. Chugh Y, Saha N, Sankaranarayanan A, Sharma PL. Memory enhancing effects of granisetron (BRL 43694) in a passive avoidance task. Eur J Pharmacol 1991;203:121-123.
25. 3 receptors. J Neurochem 1994;62:2254-2261.
26. Corradetti R, Ballerini L, Pugliese AM, Pepeu G. Serotonin blocks the long-term potentiation induced by primed burst stimulation in the CA1 region of the rat hippocampal slice. Neuroscience 1992;46:511-518.
27. 3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 1987;92:881-894.
28. 3 receptor antagonists on the elevated X-maze. J Psychopharmacol 1989;3:10P.
29. 3 receptor antagonists. Pharmacol Toxicol 1992;70: 157-162.
30. 3 receptors. Pharmacol Therap 1990;47:181-202.
31. Cupissol D, Bressolle F, Adenis L, et al. Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease. J Pharmaceut Sci 1993;82:1281-1286.
32. Davis KL, Thal LJ, Gamze ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. New Engl J Med 1992;327:1253-1259.
33. Domeney AM, Costall B, Gerrard PA, Jones DNC, Naylor RJ, Tyers MB. The effects of ondansetron on cognitive performance in the marmoset. Pharmacol Biochem Behav 1991;38:169-175.
34. 3 receptor agonists on phosphoinositides hydrolysis in the rat fronto-cingulate and entorhinal cortices. J Pharmacol Exp Ther 1991;256:1025-1032.
35. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. J Am Med Assoc 1992;268:2523-2529.
36. 3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat. Psychopharmacology 1989;99:248-251.
37. 3 receptor antagonists and anti-emetic mechanisms of action. Anti-Cancer Drugs 1992;3:79-85.
38. 3H]LY278584. Brain Res 1991;553:149-154.
39. 3 receptor antagonists: A critical update on therapeutic potential. TiPS 1993;14:265-270.
40. 3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathway. Br J Pharmacol 1990;99:227-232.
41. 3 receptor antagonists injected directly in area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 1989;97:247-255.
42. 3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal. Psychopharmacology 1991;105:322-328.
43. 3 receptor A subunit. Eur J Pharmacol 1993;254: 187-192.
44. Hornung JP, Celio MR. The selective innervation by serotonergic axons of calbindin-containing interneurons in the neocortex and hippocampus of the marmoset. J Comp Neurol 1992;320:457-467.
45. 3 receptors control dopamine release in the nucleus accumbens of freely moving rats. Neuroscience 1989;101:214-217.
46. 3 receptor antagonist. Neuropharmacology 1995;34:211-215.
47. Izquierdo I. Mechanism of action of scopolamine as an amnestic. TiPS 1989;10:175-178.
48. 3 receptor agonist 2-methylserotonin on the release of dopamine in the nucleus accumbens: An in vivo chronocoulometric study. Br Res J 1990;513:156-160.
49. 3 receptor reveals species-specific sensitivity to curare antagonism. Abstr Soc Neurosci 1992;18:249.
50. 3-receptor antagonist. Br J Pharmacol 1988;93:985-993.
51. 3 receptors in rat brain using radioligand binding. Nature 1987;330:746-748.
52. 3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons. Eur J Pharmacol 1989;169:321-324.
53. Larson J, Lynch G. Induction of synaptic potentiation in the hippocampus by patterned stimulation involves two events. Science 1986;232:985-988.
54. Lee CR, Plosker GL, McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993;46:925-943.
55. 3 receptor, a serotonin-gated ion channel. Science 1991;254:432-436.
56. 3 receptors sited on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release. J Neurochem 1992;58: 2334-2337.
57. McEntee WJ, Crook TH. Serotonin, memory and the aging brain. Psychopharmacology 1991;103:143-149.
58. 3H]GABA from slices of rat caudate-putamen. Eur J Pharmacol 1991;196:189-195.
59. Milne RJ, Heel RC. Ondansetron: Therapeutic use as an antiemetic. Drugs 1991;41:574-595.
60. 3 receptor antagonist, on the number of spontaneously active midbrain dopamine neurons. Eur J Pharmacol 1991;209:151-156.
61. 3 receptor. Abstr Soc Neurosci 1994;20:1156.
62. Morris RGM. Spatial localization does not require the presence of local cues. Learn Motiv 1981;12:239-249.
63. Newcomer JW, Faustman WO, Zipursky RB, Csernansky JG. Zacopride in schizophrenia: A single-blind serotonin type 3 antagonist trial. Arch Gen Psychiatry 1992;49:751-752.
64. O'Keefe J, Nadel L. The hippocampus as a cognitive map. Oxford: Oxford University Press, 1978.
65. 3) antagonist on electrophysiological properties of the rat hippocampus. Br J Pharmacol 1994;112:695-703.
66. Pepeu G. Memory disorders: Novel treatments, clinical perspective. Life Sci 1994;55:2189-2194.
67. 3H]quipazine in the central nervous system. Naunyn-Schmied Arch Pharmacol 1988;338:472-475.
68. 3 receptors. TiPS 1992;13:391-397.
69. 3 receptor antagonist, improves performance in the aged rat in the Morris water maze task. Neurobiol Aging 1993;14:561-564.
70. 3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task. Pharmacol Biochem Behav 1994;47:95-99.
71. Plosker GL, Goa KL. Granisetron: A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 1991;42:805-824.
72. 3 receptors in mammalian brain. TiPS 1990;11:135-137.
73. 3 receptor antagonist, causes a selective decrease in the number of spontaneously active dopaminergic neurons in the rat ventral tegmental area. Eur J Pharmacol 1992;214:13-19.
74. Riekkinen P Jr, Sirvio J, Riekkinen P. Non-reversal of scopolamine- or age-related EEG changes by ondansetron, methysergide or alaproclate. Psychopharmacology 1991;103:567-570.
75. 3 receptor antagonist with potential therapeutic relevance in central nervous system disturbances. Arzneim Forsch 1993;43:1033-1041.
76. Ropert N, Guy N. Serotonin facilitates GABAergic transmission in the rat CA1 region of the rat hippocampus in vitro. J Physiol 1991;441:121-136.
77. Rose GM, Dunwiddie TV. Induction of hippocampal long-term potentiation using physiological patterned stimulation. Neurosci Lett 1986;69:244-248.
78. 3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation. Cancer Chemother Pharmacol 1991;28:470-474.
79. Sarter M. Taking stock of cognition enhancers. TiPS 1991;12:456-461.
80. 3 receptor antagonist indicated for emesis induced by anticancer therapy. In: Bianchi AL et al., eds. Mechanism and Control of Emesis. Paris: Libbey Eurotext. 1992:227-233.
81. Schilling CJ, Marini MG, Vidi A, et al. Tolerability and pharmacokinetics of single doses of DAU 6215 CL in healthy volunteers. In: Bianchi AL, et al., eds. Mechanism and Control of Emesis. Paris: Libbey Eurotext. 1992:173-174.
82. 3 receptor antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol 1989;163:115-118.
83. 3 receptor recognition sites in the putamen of patients with Huntington's disease. Eur J Pharmacol 1993;242:137-143.
84. 3 receptor mRNA. Proc Natl Acad Sci USA 1993;90:1430-1434.
85. Teyler TJ, Discenna P. Long term potentiation. Ann Rev Neurosci 1987;10:131-161.
86. Tork I, Hornung J-P, Somogyi P. Serotonergic innervation in the cerebral cortex and hippocampus. Neurosci Lett 1988;30:131-133.
87. 3 receptor antagonists. Eur J Pharmacol 1991;203:203-211.
88. 3 receptor antagonists. J Med Chem 1990;33: 2101-2108.
89. 3 receptor antagonist itasetron (DAU 6215) on (+)-N-allynormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: An in vivo microdialysis study. J Pharmacol Exp Ther 1995;358:367.
90. 3 receptors. Eur J Pharmacol 1992;213:163-164.
91. 3H]ICS 205-930. Neuroscience 1989;31:393-400.
92. 3 receptors with high affinity in the rat brain. Eur J Pharmacol 1990;181:283-287.
93. Winson J. Loss of hippocampal theta rhythm results in spatial map memory deficit in the rat. Science 1978;201:160-163.
94. +-evoked dopamine release from rat olfactory tubercle and striatal slices. Br J Pharmacol 1994;113:968-972.